Pharmacotherapy for hepatic encephalopathy

Drugs

Volumn 70, Issue 9, 2010, Pages 1131-1148

  Phongsamran, Paula V ^a   Kim, Jiwon W ^a   Cupo Abbott, Jennifer ^a   Rosenblatt, Angela ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Riverside County Regional Medical Center   (United States)

Author keywords

Disaccharides, therapeutic use; Hepatic encephalopathy, treatment; Lactitol, therapeutic use; Lactulose, therapeutic use; Metronidazole, therapeutic use; Neomycin, therapeutic use; Rifaximin, therapeutic use; Vancomycin, therapeutic use.

Indexed keywords

4 PHENYLBUTYRIC ACID; ACARBOSE; AMMONIA; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; BROMOCRIPTINE; CARNITINE; CREATININE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; GLYCEROL PHENYLBUTYRATE; LACTITOL; LACTULOSE; MEMANTINE; METRONIDAZOLE; NEOMYCIN; NITROGEN DERIVATIVE; ORNITHINE ASPARTATE; PHENYLACETIC ACID DERIVATIVE; PROBIOTIC AGENT; PROLACTIN; RIFAXIMIN; SERUM ALBUMIN; SODIUM; SORBITOL; UNCLASSIFIED DRUG; VANCOMYCIN; ZINC;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBIOTIC RESISTANCE; BACTERIAL OVERGROWTH; BLOATING; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; CONSCIOUSNESS DISORDER; CONSTIPATION; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTERIACEAE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING LOSS; HEARING TEST; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE FLORA; INTESTINE MOTILITY; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROLACTIN BLOOD LEVEL; PROTEIN RESTRICTION; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URTICARIA; VOMITING; ZINC DEFICIENCY;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DISACCHARIDES; HEPATIC ENCEPHALOPATHY; HEPATIC INSUFFICIENCY; HUMANS; LACTULOSE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE;

EID: 77953093140     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10898630-000000000-00000     Document Type: Review

References (90)

1. Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer TD, editors. Hepatology: a textbook of liver disease. Philadelphia (PA): WB Saunders, 1996: 605-617
2. Butterworth RF, Giguere JF, Michaud J, et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-23
3. Haussinger D, Kircheis G, Fischer R, et al. Hepatic en-cephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035-1038
4. Capocaccia L, Ferenci P, Fischer JE, et al. Mechanisms of hepatic encephalopathy. Gastroenterol Int 1989; 2: 131-140
5. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2006; 25 Suppl. 1: 23-31
6. Riordan SM, Williams R. Treatment of hepatic encephalo-pathy. N Engl J Med 1997; 337 (7): 473-479
7. Mas A, Salmeron JM, Rodes J. Diagnosis and therapy of he-patic encephalopathy. Adv Exp Med Biol 1994; (368): 119-123
8. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gas-troenterol 2001; 96: 1968-1976
9. Riggio O, BalducciG, Ariosto F, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrho-tic patients with portal-systemic shunt. Dig Dis Sci 1989; 34 (6): 823-829
10. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987; 7 (6): 1278-1284
11. Morgan MY, Blei A, Grungreiff K, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007; 22: 389-405
12. Cordoba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997; 92 (9): 1429-1439
13. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora: clinical consequences. Drugs 1997; 53 (6): 930-942
14. Eroglu Y, Byrne W. Hepatic encephalopathy. Emerg Med Clin N Am 2009; 27: 401-414
15. Lactulose. Thompson Micromedex [online]. Available from URL: http://www.micromedex.com/[Accessed 2009 Oct 20]
16. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987; 7 (4): 639-643
17. Saito T, Shinzawa H, Watanabe H, et al. Home lactulose enema: prevention of hepatic encephalopathy at home. J Gastroenterol 2002; 27: 68-69
18. Heredia D, Teres J, Orteu N, et al. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic en-cephalopathy. J Hepatol 1988; 7: 106-110
19. Horsmans Y, Solbreux PM, Daenens C, et al. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11 (1): 165-170
20. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lac-tulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26 (6): 1410-1414
21. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic en-cephalopathy. Dig Dis Sci 2000; 45 (8): 1549-1552
22. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic en-cephalopathy. Hepatology 2007; 45 (3): 549-559
23. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: a randomized, cross-over study. J He-patol 1989; 8: 208-217
24. Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 1985; 26: 415-420
25. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systemic review of randomized clinical trials. BMJ 2004; 328: 1046-1051
26. Strauss E, Tramote R, Silva EPS, et al. Double-blind, ran-domized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39: 542-545
27. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981; 26: 498-506
28. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406
29. Conn HO, Leavy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double-blind controlled trial. Gastroenterology 1977; 72: 573-583
30. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54 (5): 598-609
31. Bucci L, Palmieri GC. Double-blind, double-dummy com-parison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalo-pathy. Curr Med Res Opin 1993; 13: 109-118
32. Massa P, Vallerino E, Dodero M. Treatment of hepatic en-cephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. J Clin Res 1993; 4: 7-18
33. Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 57-66
34. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalo-pathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 51-58
35. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic en-cephalopathy. Dig Dis Sci 2007; 52: 737-741
36. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46 (3): 399-407
37. Greenberg LH, Momary H. Audiotoxicity and nephro-toxicity due to orally administered neomycin. JAMA 1965; 194: 237-238
38. Berk DP, Chalmers T. Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970; 73: 393-396
39. Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet 1957; 273 (7008): 1262-1268
40. Tarao K, Ikeda T, Hayashi K, et al. Successful use of van-comycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31: 702-706
41. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23: 1-7
42. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl. 1: 36-66
43. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42 (4): 541-547
44. Huang DB, DuPont HL. Rifaximin: a novel antimicrobial for enteric infections. J Infect 2005; 50: 97-106
45. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity: a review. Chemotherapy 2005; 51 Suppl. 1: 67-72
46. Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002; 14: 290-295
47. Xifaxan (rifaximin) tablets [prescribing information]. Palo Alto (CA): Salix Pharmaceuticals, 2004 48. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73 Suppl. 1: 13-27
48. Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 175-178
49. Miglio F, Valpiani D, Rossellini SR, et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic en-cephalopathy: a double-blind, randomized trial. Curr Med Res Opin 1997; 13 (10): 593-601
50. Riggio O, Masini A, Efrati C, et al. Pharmacological pro-phylaxis of hepatic encephalopathy after transjugular in-trahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 674-679
51. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophy-laxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroentero-logy 2009; 137: 885-891
52. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362 (12): 1071-1081
53. Poordad F, Bass N, Sanyal A, et al. The protective effect of rifaximin (1100mg daily) from hepatic encephalopathy observed in a double-blind placebo controlled study is substantiated and durable over the long term [abstract]. The Liver Meeting, American Association for the Study of Liver Diseases; 2009 Oct 31; Boston (MA)
54. Huang E, Esrailian E, Spiegel BMR. The cost-effectiveness and budget impact of competing therapies in hepatic en-cephalopathy: a decision analysis. Aliment Pharmacol Ther 2007; 26: 1147-1161
55. Sama Ca, Morselli-Labate AM, Pianta P, et al. Clinical ef-fects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label, pilot study. Clin Ther Res 2004; 65 (5): 413-420
56. Neff GW, Kemmer N, Zacharias T, et al. Analysis of hos-pitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006; 38: 3552-3555
57. Morgan MY. Branched chain amino acids in the manage-ment of chronic liver disease: facts and fantasies. J Hepatol 1990; 11: 133-141
58. James JH, Ziparo V, Jeppsson B, et al. Hyperammonaemia, plasma amino-acid balance, and blood-brain amino-acid transport: a unified theory of portal-systemic encephalo-pathy. Lancet 1979; 2: 772-775
59. Horst d, Grace ND, Conn Ho, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279-287
60. Marchesini G, Dioguardi FS, Bianchi GP, et al. Long-term branched chain amino acid treatment in chronic hepatic encephalopathy. J Hepatol 1991; 11: 92-101
61. Naylor CD, O'Rouke K, Detsky As, et al. Parenteral nutri-tion with branched-chain amino acids in hepatic en-cephalopathy: a meta-analysis. Gastroenterology 1989; 97: 1033-1042
62. Als-Nielsen B, Koretz RL, Kjaergard LL, et al. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003; (2): CD001939
63. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001; 109: 52-90
64. Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis: a double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19: 424-430
65. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1998; 25: 1351-1360
66. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 856-864
67. Acharya SK, Bhatia V, Sreenivas V, et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136: 2159-2168
68. Loomba V, Pawar G, Khar KL, et al. Serum zinc levels in hepatic encephalopathy. Indian J Gastroenterol 1995; 14: 51-53
69. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic en-cephalopathy: results of a double-blind crossover trial. Dig Dis Sci 1991; 36: 1204-1208
70. Marchesini G, Fabbri A, Bianchi G, et al. Zinc supple-mentation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996; 23: 1084-1092
71. Van der Rijt CC, Schalm SW, Schat H, et al. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastro-enterology 1991; 100: 1114-1118
72. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16: 138-144
73. Pomier-Layrargues G, Rose C, Spahr L, et al. Role of manganese in the pathogenesis of portal-systemic en-cephalopathy. Metab Brain Dis 1998; 13: 311-317
74. Uribe M, Farca A, Marquez MA, et al. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 1979; 76: 1347-1351
75. Gyr K, Meier R, Haussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996; 39: 319-324
76. Cadranel JF, el Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995; 7: 325-329
77. Pomier-Layrargues JF, Giguere JF, Javoie J, et al. Fluma-zenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatol-ogy 1994; 19: 32-37
78. Van der Rijt CC, Schalm SW, Meulstee J, et al. Flumazenil therapy for hepatic encephalopathy: a double-blind cross over study. Gastroenterol Clin Biol 1995; 19: 572-580
79. Barbaro G, Dilorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo controlled, cross-over study. Hepatology 1998; 28: 374-378
80. Als-Nielsen B, Kjaergard Ll, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2004; (2): CD002798
81. Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3: 184-191
82. Liu Q, Duan ZP, Ha da K, et al. Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 1994; 39: 1441-1449
83. Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 39-46
84. Bajaj JS, Saejan K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707-1715
85. Sharma P, Sharma BC, Puri V, et al. An open-label ran-domized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gas-troenterol Hepatol 2008; 20: 506-511
86. Malaguarnera M, Greco F, Barone G, et al. Bifidobac-terium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52: 3259-3265
87. Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11: 7197-7202
88. del Olmo JA, Castillo M, Rodrigo JM, et al. Effects of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv Exp Med Biol 1990; 272: 197-208
89. A study of the safety and efficacy of HPN-100 for main-taining remission in subjects with cirrhosis and episodic hepatic encephalopathy (HALT-HE) [ClinicalTrials.gov identifier NCT00999167]. US National Institute of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 May 3]
90. Vogels BA, Maas MA, Daalhuisen J, et al. Memantine, a noncompetitive NMDA receptor antagonist improves hy-perammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997; 25: 820-827